Therapeutic Science and Strategy

Pharma portfolios can create powerful opportunities, but without clear positioning, brands can end up competing with each other. In this episode, Lumanity's Jakub Kaczor, VP, Strategy Consulting, and Peter Smith, SVP, Strategy Consulting, discuss the complexities of portfolio positioning in the pharmaceutical industry. The guests explain that while a focused R&D strategy drives commercial growth a...

In the volatility caused by policy convergence, the future belongs to organizations that can intelligently navigate inflection points that precede launch In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity discusses how policy shifts are converging to compress pharma revenue opportunity and force decisive commercial choices much earlier in development. He highli...

Most pharma launch frameworks don't fail because they lack structure; they fail because they become rigid checklists that kill strategic thinking. In this episode, Lumanity's Launch Excellence Project Lead, Jeff Hart, and Launch Excellence Principal, Kirsty Tait, talk about how pharmaceutical companies can scale launch excellence as pipelines grow and complexity increases. Kirsty and Jeff explain...

Launching a pharma product is a high-stakes, pressure-filled marathon where poor planning shows up too late to fix. In this episode, Andrew Mooney and Laurence Cooper break down how early planning, focused strategy, and disciplined execution help smaller pharma teams succeed in high-pressure launches. If you're preparing for a first-time or early-stage pharma launch, this conversation breaks down...

Great pharma brands don't wait for the market to define them; they define themselves through clear, early, and evolving positioning. In this episode, Vice President Natalie Thovmasian and Managing Consultant Liv Yates, highlight that brand positioning is a strategic driver across the entire pharma lifecycle, not just a launch activity. They stress the importance of shaping positioning early, befor...

In the third episode of our Patient Progress podcast series, we look at the hidden and not-so-hidden barriers that keep marginalized communities from getting the mental and physical healthcare they need.  Advocates Sarah Renee and Daniel Newman join host Jenny Payne for a candid conversation about how cost, stigma, and institutional biasintersect to make care harder to reach—and how these obstacle...

In Episode 2 of our Patient Progress podcast series, we hear directly from those living with mental illness about the obstacles they face: the cost of care, insurance hurdles, and the lack of consistent support services that can mean the difference between getting well and going without. Advocates Kody Green and Gabe Howard share candid stories that reveal why access and affordability aren't just...

During this conversation with Outcomes Rocket, Sandy Richardson and Zoe Brown, Principals at Lumanity, talk about why organizations struggle to turn massive amounts of competitive intelligence into actionable strategy. In part 2, Sandy and Zoe discuss how companies can move beyond information overload to build true competitive readiness through focus, collaboration, and action. They explain why re...

During this conversation, Sandy Richardson and Zoe Brown, Principals at Lumanity, talk about why organizations struggle to turn massive amounts of competitive intelligence into actionable strategy. In part 1, Sandy and Zoe explain how today's "sea of sameness" makes true differentiation harder than ever, and how teams often remain "data rich but time poor," missing early signals of competitive thr...

Caregivers are often the unsung heroes of healthcare: key decision‑makers, advocates, researchers, and emotional anchors. Yet, support for their own mental health is frequently absent. In this episode, Lumanity's Jenny Payne sits down with Ashlee Cramer and Ceinwen Giles to break misconceptions ("Caregivers are saints and happy to do it") and discuss the real impact — from anxiety, depression, and...

During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference.  Their conversation covers a variety of topics, including: The importance of the patient and including the patient voice in drug development The way that Artificial Intelligence (AI) could impact and in...

In this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research

In our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change. Our discussion includes: The importance of evaluating concepts using the right criteria Generating maximum impact using clear and simple ads tha...

In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmac...

In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making. Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include: How the agility, flexibility and insights from SML research are being harnessed to help impro...

In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making. Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavior...

There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends.  Listen to this podcast to learn: ·          Key...

Strategic risk is often overlooked within the pharmaceutical industry. There's a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitiga...

We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from 'leading from the front', towards a model that champions interdependent leadersh...

In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022. This episode covers: An overview of the IRA in relation to healthcare The potential impacts for oncology patients, manufacturers, and oncologists The impact of the legislation outside of the U.S. Speakers: Nancy McGee, JD, MPH, DrPH...

During the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?" But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful lau...

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content. In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss : Company origins, focus, and fundraising performance to date Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity Performance o...

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fifth episode, Joel sits down with Brian Leyland-Jones, MB BS, PhD, CMO, National Foundation for Cancer Research and Peter Kuhn, PhD, Dean's Professor of Biological Sciences, Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mech...

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this fourth episode, Joel sits down with Jeff Bockman, Executive Vice President and Head of Oncology at Lumanity, and Michael Curran, PhD, Associate Professor, Department of Immunology, The University of Texas, MD Anderson Cancer Center, to explore: • The effort to...

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content. In this third episode, Joel sits down with Michael 'Mitch' Petrick, anaplastic thyroid cancer patient, to explore: Mitch's background and his rare form of thyroid cancer His journey from initial diagnosis (which he made!) through to referral and treatment Some thoughts...